The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer.

Autor:	Erkoc M; Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey., Otunctemur A; Department of Urology, Prof. Dr Cemil Tascioglu City Hospital, Istanbul, Turkey., Bozkurt M; Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey., Can O; Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey., Atalay HA; Department of Urology, Beylikduzu State Hospital, Istanbul, Turkey., Besiroglu H; Department of Urology, Istanbul-Cerrahpasa University Faculty of Medicine, Istanbul, Turkey., Danis E; Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey., Degirmentepe RB; Department of Urology, Of State Hospital, Trabzon, Turkey.
Jazyk:	angličtina
Zdroj:	International journal of clinical practice [Int J Clin Pract] 2021 Sep; Vol. 75 (9), pp. e14584. Date of Electronic Publication: 2021 Jul 09.
DOI:	10.1111/ijcp.14584
Abstrakt:	Objective: Our study aims to evaluate the efficiency and reliability of Vesical Imaging Reporting Data System (VI-RADS) in prospectively identifying the patients to undergo RE-TURBT in the management of patients with high-risk non-muscle invasive Bladder Cancer(HR-NMIBC).The secondary objective was to evaluate the performance of the VI-RADS scoring system in differentiating between muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer(NMIBC) prospectively. Methods: The study included 330 patients who underwent transurethral resection of bladder tumour(TURBT) for Bladder Cancer (BC) in our clinic. All patients underwent multiparametric-magnetic resonance imaging (Mp-MRI) before the operation and VI-RADS scoring was administered. The cut-off value of VI-RADS was accepted as three and above. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for the differentiation between NMIBC and MIBC distinction in all patients. Receiver operating characteristic (ROC) analysis was performed to evaluate the performance of the VI-RADS scoring system. In the second phase of the study, patients with MIBC and low-risk NMIBC (LR-NMBIC) were excluded and 158 patients with HR-NMIBC were included, and their sensitivity, specificity, PPV and NPV values were measured. ROC analysis was performed. Results: In all patients, sensitivity, specificity, PPV and NPV values of the VI-RADS scoring in the differentiation of MIBC and NMIBC were 91.3, 91.8, 81.7 and 96.3 respectively. The AUC value was 0.934 (95%CI: 0.903-0.964). Sensitivity, specificity, PPV and NPV values were found to be 87, 91.8, 74.1, 95.2 in the evaluation specifically made for patients with HR-NMIBC. The AUC value was 0.900 (95% CI:0.843-0.957). Inter-reader agreement was excellent (Ƙ = 0.90, 95% CI:0.71-0.95). Conclusions: The VI-RADS scoring system is an effective and reliable method in determining the patients who will undergo RE-TURBT and in differentiating MIBC and NMIBC. (© 2021 John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu